FindTrial
Sign In

J5D-MC-FPAD: A Phase 2a, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524726-18-00
Enrollment
6
Registered
2026-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Segmental Vitiligo (NSV), Vitiligo

Brief summary

Percentage of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI) 75

Interventions

DRUGSUB12581MIG

Sponsors

Eli Lilly & Co.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Percentage of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI) 75—

Outcome results

None listed

Source: EU CTIS · Data processed: May 30, 2026